Interestingly, although TOX3 was generally low in AML patients, its expression in AML-M5 patients (median: 2.04) was significantly higher than that in AML-M2 patients, and it had the following expression pattern: AML-M5 > AML-M3 > AML-M2 (AML-M5 vs. AML-M3: P = 0.193; AML-M3 vs. AML-M2: P = 0.837; AML-M5 vs. AML-M2: P = 0.028). The gene discussed is TOX3; the disease is acute myeloid leukemia.